Gain Therapeutics reports stable MDS-UPDRS scores at Day 150 in Phase 1b trial of Parkinson’s drug GT-02287

• Gain Therapeutics presented new interim Phase 1b extension data for Parkinson’s drug candidate GT-02287 at the 3rd International GBA1 Meeting 2026.
• Clinical scores were broadly stable over five months of dosing, supporting a potential disease-modifying profile.
• Participants with higher baseline disease-related biomarkers showed a clearer clinical response than those with lower baseline levels.
• Biomarker shifts were consistent with an effect on underlying Parkinson’s biology, reinforcing the rationale to advance development.
• Planning for a Phase 2 trial includes formal testing of patient-reported functional changes such as smell, sleep, and gait.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gain Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605260800PRIMZONEFULLFEED9726408) on May 26, 2026, and is solely responsible for the information contained therein.